Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session - Breast cancer, metastatic

LBA15 - Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer

Date

19 Sep 2021

Session

Proffered Paper session - Breast cancer, metastatic

Topics

Tumour Site

Breast Cancer

Presenters

Cristina Saura Manich

Citation

Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741

Authors

C. Saura Manich1, J. O'Shaughnessy2, P.G. Aftimos3, E. van den Tweel4, M. Oesterholt4, S.I. Escrivá-de-Romaní1, N. Quenel Tueux5, T.J. Tan6, J.S. Lim7, S. Ladoire8, A. Armstrong9, T. Crook10, A. Stradella11, G. Bianchi12, R. Mulder4, N. Koper4, N. Turner13

Author affiliations

  • 1 Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, 8035 - Barcelona/ES
  • 2 Breast Oncology, Baylor University Medical Center / Texas Oncology, TX 75246 - Dallas/US
  • 3 Clinical Trials Conduct Unit, Institut Jules Bordet - Université Libre de Bruxelles, 1000 - Brussels/BE
  • 4 Clinical Development, Byondis B.V., 6503GB - Nijmegen/NL
  • 5 Medical Oncology, Institut Bergonie, 33076 - Bordeaux/FR
  • 6 Division Of Medical Oncology, National Cancer Centre Singapore, 169610 - Singapore/SG
  • 7 Department Of Hemato-oncology, National University Cancer Institute, 199228 - Singapore/SG
  • 8 Oncology, Centre Georges-François Leclerc (Dijon), 21000 - Dijon/FR
  • 9 The Christie Clinic - Medical Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 10 Medical Oncology, Sarah Cannon Research Institute, W1G6AD - London/GB
  • 11 Medical Oncology, Institut Català d’Oncologia - Hospitalet, 8908 - Barcelona/ES
  • 12 Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milano/IT
  • 13 Breast Oncology, The Royal Marsden Hospital / ICR, SW3 6JJ - London/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract LBA15

Background

[vic-]Trastuzumab duocarmazine (SYD985, Byondis B.V., NL) is a novel HER2-targeting antibody–drug conjugate comprised of trastuzumab bound to a linker drug containing duocarmycin. TULIP assessed the efficacy of SYD985 in advanced HER2-positive breast cancer.

Methods

The TULIP trial (NCT03262935) randomly assigned HER2-positive locally advanced or metastatic breast cancer (MBC) patients with ≥ 2 previous MBC regimens or previous MBC treatment with T-DM1, 2:1 between SYD985 (1.2 mg/kg q three weeks) and physician’s choice (PC) chemotherapy. The primary endpoint was progression-free survival (PFS) by blinded central review. The trial was powered to detect a Hazard Ratio (HR) of 0.65 at the P < 0.05 significance level. Secondary endpoints were investigator-assessed PFS, overall survival (OS), objective response rate (ORR), and health-related quality of life (HRQoL).

Results

437 patients from 11 countries were randomized to SYD985 (n=291) or PC (n=146). Median age was 56 years, median number of prior MBC treatments was 4 [range 1-16]. Centrally reviewed median PFS was 7.0 months [95% CI 5.4-7.2] for SYD985 and 4.9 mo [4.0-5.5] for PC (HR 0.64 [0.49-0.84]; p = 0.002). Investigator-assessed PFS was also significantly improved (6.9 mo [6.0-7.2] vs 4.6 mo [4.0-5.6]; HR 0.60 [0.47-0.77]; p < 0.001). In this first analysis of OS the HR was 0.83 [0.62-1.09]; p = 0.153. No significant differences were observed in ORR or HRQoL. The most frequently reported adverse events for SYD985 were conjunctivitis (38.2%), keratitis (38.2%) and fatigue (33.3%), for PC these were diarrhoea (35.8%), nausea (31.4%) and fatigue (29.9%). Interstitial lung disease / pneumonitis was reported for 7.6% (5.2% grade 1-2) of patients treated with SYD985, including two grade 5 events. Adverse events leading to discontinuation (SYD985 35.4%, PC 10.2%) in the SYD985 group were mainly related to eye disorders (20.8%) or respiratory disorders (6.3%).

Conclusions

Treatment with SYD985 significantly improved PFS in comparison with standard PC and may provide a new treatment option for patients with pre-treated locally advanced or metastatic HER2-positive MBC.

Clinical trial identification

NCT03262935.

Editorial acknowledgement

Legal entity responsible for the study

Byondis B.V., Nijmegen, The Netherlands.

Funding

Byondis B.V.

Disclosure

C. Saura Manich: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Personal, Advisory Board: Exact Sciences; Financial Interests, Personal, Advisory Board: Exeter Pharma; Financial Interests, Personal, Advisory Board: F. Hoffmann - La Roche Ltd; Financial Interests, Personal, Advisory Board: MediTech; Financial Interests, Personal, Advisory Board: Merck Sharp & Dohme; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Philips; Financial Interests, Personal, Advisory Board: Piere Fabre; Financial Interests, Personal, Advisory Board: Puma; Financial Interests, Personal, Advisory Board: Roche Farma; Financial Interests, Personal, Advisory Board: Sanofi Aventis; Financial Interests, Personal, Advisory Board: SeaGen; Financial Interests, Personal, Advisory Board: Zymeworks; Financial Interests, Personal, Other, SC: Byondis B.V.; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: Daiichi Sankyo; Financial Interests, Institutional, Research Grant: Eli Lilly and Company; Financial Interests, Institutional, Research Grant: Genentech; Financial Interests, Institutional, Research Grant: Immunomedics; Financial Interests, Institutional, Research Grant: Macrogenics; Financial Interests, Institutional, Research Grant: Merck, Sharp and Dhome España S.A.; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Research Grant: Piqur Therapeutics; Financial Interests, Institutional, Research Grant: Puma; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Research Grant: Synthon; Financial Interests, Institutional, Research Grant: Zenith Pharma; Financial Interests, Institutional, Invited Speaker: Byondis B.V.; Non-Financial Interests, Member: Spanish Society of Medical Oncology (SEOM); Non-Financial Interests, Member: American Society for Clinical Oncology (ASCO); Non-Financial Interests, Member: SOLTI group (Academic research group in breast cancer); Non-Financial Interests, Member: Geicam (Spanish Breast Cancer Research Group); Non-Financial Interests, Member: American Association for Cancer Research (AACR). J. O'Shaughnessy: Financial Interests, Personal, Advisory Board: AbbVie Inc; Financial Interests, Personal, Advisory Board: Agendia; Financial Interests, Personal, Advisory Board: Aptitude Health; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Celgene Corporation; Financial Interests, Personal, Advisory Board: Clovis Oncology; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Personal, Advisory Board: G1 Therapeutics; Financial Interests, Personal, Advisory Board: Genentech; Financial Interests, Personal, Advisory Board: Gilead Sciences; Financial Interests, Personal, Advisory Board: GRAIL; Financial Interests, Personal, Advisory Board: Halozyme Therapeutics; Financial Interests, Personal, Advisory Board: Heron Therapeutics; Financial Interests, Personal, Advisory Board: Immunomedics; Financial Interests, Personal, Advisory Board: Ipsen Biopharmaceuticals; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Advisory Board: Myriad; Financial Interests, Personal, Advisory Board: Nektar Therapeutics; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Ontada; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Pharmacyclics; Financial Interests, Personal, Advisory Board: Pierre Fabre Pharmaceuticals; Financial Interests, Personal, Advisory Board: Puma Biotechnology; Financial Interests, Personal, Advisory Board: Prime Oncology; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Samsung Bioepis; Financial Interests, Personal, Advisory Board: Sanofi; Financial Interests, Personal, Advisory Board: Seagen; Financial Interests, Personal, Advisory Board: Syndax Pharmaceuticals; Financial Interests, Personal, Advisory Board: Taiho Oncology; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal, Advisory Board: Synthon B.V.; Financial Interests, Personal, Advisory Board: Byondis B.V. P.G. Aftimos: Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: Macrogenics; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Amcure; Financial Interests, Personal, Advisory Board: Servier; Financial Interests, Personal, Advisory Board: G1 Therapeutics; Financial Interests, Personal, Advisory Board: Radius; Financial Interests, Personal, Advisory Board: Deloitte; Financial Interests, Personal, Advisory Board: Menarini; Financial Interests, Personal, Advisory Board: Synthon; Financial Interests, Personal, Advisory Board: Byondis; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Role: Gilead; Non-Financial Interests, Personal, Other, Travel grant: MSD; Non-Financial Interests, Personal, Other, Travel grant: Pfizer; Financial Interests, Institutional, Funding: Roche; Financial Interests, Personal, Advisory Board: Sanofi-Aventis; Non-Financial Interests, Personal, Other, Travel grant: Roche; Non-Financial Interests, Personal, Other, Travel grant: Amgen; Non-Financial Interests, Personal, Other, Member of the scientific committee: IBCSG. E. van den Tweel: Financial Interests, Personal, Full or part-time Employment: Byondis B.V.; Non-Financial Interests, Personal, Member: ESMO; Non-Financial Interests, Personal, Member: ASCO. M. Oesterholt: Financial Interests, Personal, Full or part-time Employment: Byondis B.V. S.I. Escrivá-de-Romaní: Financial Interests, Personal, Invited Speaker, Advisory board, Travel grants: Roche; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Personal, Advisory Board, Invited speaker, travel grants: Daiichi Sankyo; Financial Interests, Personal, Advisory Board, Invited speaker, travel grant: Pierre Fabre; Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Institutional, Research Grant: Zymeworks; Financial Interests, Institutional, Research Grant: Synthon B.V.; Financial Interests, Institutional, Research Grant: Byondis B.V.; Financial Interests, Personal, Advisory Board: Seagen. N. Quenel Tueux: Financial Interests, Institutional, Principal Investigator: Byondis B.V. T.J. Tan: Financial Interests, Personal and Institutional, Advisory Board, Invited speaker, Board & Principal Investigator: Novartis; Financial Interests, Personal and Institutional, Advisory Board, Principal Investigator: Roche; Financial Interests, Personal, Speaker’s Bureau, Advisory board: DKSH; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Invited Speaker, Advisory board: MSD; Financial Interests, Personal and Institutional, Invited Speaker, Advisory board, Principal Investigator, Research grant: AstraZeneca; Non-Financial Interests, Institutional, Principal Investigator: Seagen. J.S. Lim: Financial Interests, Personal, Invited Speaker, Advisory board: AstraZeneca; Financial Interests, Personal, Advisory Board, Invited speaker: DKSH; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Invited Speaker: Pierre Fabre; Financial Interests, Personal, Invited Speaker: Roche; Non-Financial Interests, Institutional, Funding: CTI Biopharma; Non-Financial Interests, Institutional, Principal Investigator: Daiichi Sankyo; Non-Financial Interests, Institutional, Principal Investigator: Byondis B.V.; Non-Financial Interests, Institutional, Principal Investigator: Synthon B.V.; Non-Financial Interests, Institutional, Principal Investigator: Taiho Pharmaceuticals. S. Ladoire: Financial Interests, Institutional, Principal Investigator: Byondis B.V. A. Armstrong: Financial Interests, Institutional, Principal Investigator: Byondis B.V. T. Crook: Financial Interests, Institutional, Principal Investigator: Byondis B.V.; Financial Interests, Personal, Invited Speaker: Eli Lilly; Financial Interests, Personal, Advisory Board: Eli Lilly; Financial Interests, Personal, Advisory Board: Daiichi Sankyo. A. Stradella: Financial Interests, Institutional, Principal Investigator: Byondis B.V.; Financial Interests, Personal, Invited Speaker: Pierre Fabre; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal and Institutional, Expert Testimony: Seagen. G. Bianchi: Financial Interests, Institutional, Principal Investigator: Byondis B.V.; Financial Interests, Personal, Advisory Board: Eli Lilly; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Roche. R. Mulder: Financial Interests, Personal, Full or part-time Employment: Byondis B.V. N. Koper: Financial Interests, Personal, Full or part-time Employment: Byondis B.V. N. Turner: Financial Interests, Institutional, Principal Investigator: Byondis B.V.; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Merck Sharpe and Dohme; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Roche/Genentech; Financial Interests, Personal, Advisory Board: Bicycle Therapeutics; Financial Interests, Personal, Advisory Board: Taiho; Financial Interests, Personal, Advisory Board: Zeno Phamraceuticals; Financial Interests, Personal, Advisory Board: Repare therapeutics; Financial Interests, Institutional, Funding: AstraZeneca; Financial Interests, Institutional, Funding: BioRad; Financial Interests, Institutional, Funding: Pfizer; Financial Interests, Institutional, Funding: Roche/Genentech; Financial Interests, Institutional, Funding: Clovis; Financial Interests, Institutional, Funding: MSD; Financial Interests, Institutional, Funding: Guardant Health; Non-Financial Interests, Personal, Advisory Board: Byondis B.V.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.